A study to assess the efficacy and safety of KRN23 in adults with X-linked Hypophosphatemia (XLH)

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-005529-11

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Establish the effect of KRN23 treatment compared with placebo on increasing serum phosphorus levels in adults with XLH


Critère d'inclusion

  • XLH is a disorder of hypophosphatemia, renal phosphate wasting, and the most common inheritable form of rickets. In XLH patients, excess circulating fibroblast growth factor (FGF23) impair phosphate reabsorption in the kidney. Chronic low serum phosphorus levels lead to defective bone mineralization and, consequently, to rickets in children and osteomalacia in adults, the two major pathologic outcomes of the hypophosphatemia

Liens